Dr. Rajan Ravikumar, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- Rutgers New Jersey Medical School (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 116
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Rutgers New Jersey Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
MI license 4301076537 · PA license MD428811 -
Internal Medicine Physician
MI license 4301076537
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 116
- Services billed
- 191
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 293 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 85 | 76 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| New patient office or other outpatient visit, 30-44 minutes | 22 | 22 |
| Established patient office or other outpatient visit, 20-29 minutes | 20 | 20 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dupixent Pen (dupilumab) Other prescribers in Brighton, MI | 59 |
| Montelukast Sodium Other prescribers in Brighton, MI | 59 |
| Xolair (omalizumab) | 53 |
| Azelastine Hcl Other prescribers in Brighton, MI | 46 |
| Fluticasone Propionate Other prescribers in Brighton, MI | 39 |
| Ipratropium Bromide Other prescribers in Brighton, MI | 31 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Brighton, MI | 26 |
| Dupixent Syringe (dupilumab) Other prescribers in Brighton, MI | 23 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Brighton, MI | 21 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Brighton, MI | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $249 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $183 |
|---|---|
| Teva Pharmaceuticals USA, Inc. | $65.90 |
| Food and Beverage | $249 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $263,742 in research payments for these studies, mostly to the institutions running them.
- The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sanofi US Services Inc. · Active, not recruiting · NCT06241118 - Study name not reported
Ionis Pharmaceuticals, Inc. - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.